Hotchkis & Wiley Capital Management 13F: Adds $105M to LH Stake

Hotchkis & Wiley Capital Management has significantly boosted its holdings in Labcorp Holdings Inc. (NYSE:LH), according to its latest Form 13F filing with the SEC. The firm added 374,664 shares during the reporting period, bringing its total to 743,602 shares. This represents a 101.6% increase in its stake, now valued at approximately $207.9 million.

What Changed in Hotchkis & Wiley's Labcorp Position

Hotchkis & Wiley Capital Management doubled its investment in Labcorp Holdings Inc., adding 374,664 shares to its portfolio. This move increased its position by 101.6%, with the total shares held now at 743,602, valued at around $207.9 million. The firm previously held 368,938 shares.

Other Institutional Activity in Labcorp

Other institutional investors also made notable moves in Labcorp. BlackRock, Inc. trimmed its holdings by 95,925 shares, maintaining a total of 6,444,856 shares valued at $1.72 billion. Vanguard Capital Management LLC opened a new position with 5,376,120 shares worth about $1.43 billion. Victory Capital Management Inc. reduced its stake by 729,699 shares, leaving it with 4,627,126 shares valued at $1.23 billion. State Street Corp added 36,844 shares, now holding 3,863,171 shares valued at $1.03 billion. Boston Partners increased its holdings by 455,101 shares, bringing its total to 2,368,796 shares worth $632.4 million.

Labcorp Holdings Inc. Stock Down 12.8%

Shares of Labcorp Holdings Inc. traded near $279.58 on Tuesday. The company has a market cap of $22.3 billion and a P/E ratio of 24.0. Its stock has ranged from a 52-week low of $241.81 to a high of $293.72. The 50-day moving average stands at $260.81, while the 200-day moving average is $267.15. Labcorp's beta is 0.877, indicating its relative volatility compared to the market.

Recent Earnings

Labcorp reported revenue of approximately $14.14 billion, reflecting a growth rate of 5.8%. The company's net margin is 6.66%, with a return on equity of 11.05%. The next earnings report is expected on July 23, 2026.

Dividend

Labcorp pays an annual dividend rate of $2.88, yielding 1.06% with a payout ratio of 25.51%.

Insider Buying and Selling at Labcorp Holdings Inc.

Recent insider transactions at Labcorp included several planned sales. EVP and Chief Legal Officer Kathryn Kyle sold 762 shares on June 8, 2026, at an average price of $263.89. President and CEO Adam Schechter sold 5,903 shares on May 11, 2026, at $254.50. Other executives like EVP of Operations Jonathan Meltzer and SVP Chief Accounting Officer Peter Wilkinson also executed sales in March.

Analysts Set New Price Targets

On April 8, 2026, Evercore ISI Group maintained its 'buy' rating for Labcorp with a price target of $300. Piper Sandler also maintained a 'hold' rating with the same price target on February 24, 2026. JP Morgan reiterated its 'buy' rating with a $330 target on February 18, 2026. The consensus among analysts is a 'buy' recommendation with a mean target price of $310.12 across 17 opinions.

About Labcorp Holdings Inc.

Labcorp Holdings Inc. is a major player in the healthcare sector, specializing in diagnostics and research. Based in Burlington, North Carolina, the company provides a wide range of laboratory services, including blood chemistry analyses, specialty testing, and digital pathology solutions. Labcorp operates in two segments: Diagnostics Laboratories and Biopharma Laboratory Services. Led by CEO Adam H. Schechter, Labcorp employs approximately 71,000 people.

Bottom Line

Hotchkis & Wiley Capital Management's decision to significantly increase its stake in Labcorp Holdings Inc. reflects a strong interest in the company's potential. While institutional activity shows varied movements, Labcorp remains a key player in the diagnostics and research industry. Investors should note that 13F filings are backward-looking and may not represent the current position of the firm.